| Reinforcement learning in healthcare: A survey C Yu, J Liu, S Nemati, G Yin ACM Computing Surveys (CSUR) 55 (1), 1-36, 2021 | 781 | 2021 |
| Root canal filled versus non‐root canal filled teeth: a retrospective comparison of survival times DJ Caplan, J Cai, G Yin, BA White Journal of public health dentistry 65 (2), 90-96, 2005 | 294 | 2005 |
| ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous … KS Klos, SL Wyszomierski, M Sun, M Tan, X Zhou, P Li, W Yang, G Yin, ... Cancer research 66 (4), 2028-2037, 2006 | 228 | 2006 |
| Bayesian model averaging continual reassessment method in phase I clinical trials G Yin, Y Yuan Journal of the American Statistical Association 104 (487), 954-968, 2009 | 216 | 2009 |
| Cure rate models: a unified approach G Yin, JG Ibrahim Canadian Journal of Statistics 33 (4), 559-570, 2005 | 213 | 2005 |
| Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios G Yin, Y Li, Y Ji Biometrics 62 (3), 777-787, 2006 | 205 | 2006 |
| Bayesian dose finding in oncology for drug combinations by copula regression G Yin, Y Yuan Journal of the Royal Statistical Society Series C: Applied Statistics 58 (2 …, 2009 | 200 | 2009 |
| Nonparametric maximum likelihood approach to multiple change-point problems C Zou, G Yin, L Feng, Z Wang | 176 | 2014 |
| Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma E Rivera, C Meyers, M Groves, V Valero, D Francis, B Arun, K Broglio, ... Cancer 107 (6), 1348-1354, 2006 | 176 | 2006 |
| HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors M Sun, C Behrens, L Feng, N Ozburn, X Tang, G Yin, R Komaki, ... Clinical cancer research 15 (15), 4829-4837, 2009 | 173 | 2009 |
| Clinical trial design: Bayesian and frequentist adaptive methods G Yin John Wiley & Sons, 2012 | 172 | 2012 |
| Semiparametric transformation models for survival data with a cure fraction D Zeng, G Yin, JG Ibrahim Journal of the American Statistical Association 101 (474), 670-684, 2006 | 171 | 2006 |
| Bayesian quantile regression for longitudinal studies with nonignorable missing data Y Yuan, G Yin Biometrics 66 (1), 105-114, 2010 | 155 | 2010 |
| Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung P Yuan, H Kadara, C Behrens, X Tang, D Woods, LM Solis, J Huang, ... PloS one 5 (2), e9112, 2010 | 146 | 2010 |
| Upregulation and activation of PKCα by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKCα and Src inhibitors M Tan, P Li, M Sun, G Yin, D Yu Oncogene 25 (23), 3286-3295, 2006 | 136 | 2006 |
| A latent contingency table approach to dose finding for combinations of two agents G Yin, Y Yuan Biometrics 65 (3), 866-875, 2009 | 130 | 2009 |
| Bayesian dose finding by jointly modelling toxicity and efficacy as time-to-event outcomes Y Yuan, G Yin Journal of the Royal Statistical Society Series C: Applied Statistics 58 (5 …, 2009 | 124 | 2009 |
| Phase 3 study comparing the use of docetaxel on an every‐3‐week versus weekly schedule in the treatment of metastatic breast cancer E Rivera, JA Mejia, BK Arun, RB Adinin, RS Walters, A Brewster, ... Cancer 112 (7), 1455-1461, 2008 | 121 | 2008 |
| Bayesian optimal interval design for dose finding in drug-combination trials R Lin, G Yin Statistical methods in medical research 26 (5), 2155-2167, 2017 | 98 | 2017 |
| Outlier detection for high-dimensional data K Ro, C Zou, Z Wang, G Yin Biometrika 102 (3), 589-599, 2015 | 98 | 2015 |
Ruitao LinThe University of Texas MD Anderson Cancer CenterGeverifieerd e-mailadres voor mdanderson.org